GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eris Lifesciences Ltd (BOM:540596) » Definitions » Total Equity

Eris Lifesciences (BOM:540596) Total Equity : ₹32,220 Mil (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Eris Lifesciences Total Equity?

Eris Lifesciences's total equity for the quarter that ended in Mar. 2024 was ₹32,220 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Eris Lifesciences Total Equity Historical Data

The historical data trend for Eris Lifesciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eris Lifesciences Total Equity Chart

Eris Lifesciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12,963.34 15,764.23 19,082.03 22,206.77 32,220.31

Eris Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22,206.77 - 24,275.73 - 32,220.31

Eris Lifesciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Eris Lifesciences's Total Equity for the fiscal year that ended in Mar. 2024 is calculated as

Total Equity=Total Assets(Q: Mar. 2024 )-Total Liabilities(Q: Mar. 2024 )
=70488.37-38268.06
=32,220

Eris Lifesciences's Total Equity for the quarter that ended in Mar. 2024 is calculated as

Total Equity=Total Assets(Q: Mar. 2024 )-Total Liabilities(Q: Mar. 2024 )
=70488.37-38268.06
=32,220

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eris Lifesciences Total Equity Related Terms

Thank you for viewing the detailed overview of Eris Lifesciences's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Eris Lifesciences (BOM:540596) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eris Lifesciences Ltd (BOM:540596) » Definitions » Total Equity
Comparable Companies
BOM:506820 BOM:543635 BOM:524816 BOM:543064 BOM:533573 BOM:500126 BOM:532482 BOM:524742 BOM:543322 BOM:532872 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
ERIS:India
Address
Ramdas Road, Plot No. 142/2, Shivarth Ambit, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, GJ, IND, 380054
Website
https://www.eris.co.in
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast.

Eris Lifesciences (BOM:540596) Headlines

No Headlines